Nutrition 21 successfully challenges competitor comparison claims as unsubstantiated
NEW YORK — The National Advertising Division last week recommended that Interhealth Nutraceuticals discontinue certain claims for the company’s Zychrome dietary supplements, products that are promoted for the management of insulin levels.
Print and internet claims made by Interhealth for its Zychrome chromium compound, also known as chromium dinicocysteinate, were challenged by Nutrition 21, the manufacturer of a competing product, Chromax, a chromium picolinate product. Interhealth had been making comparison claims against the supplement ingredient in Chromax.
Following its review of the evidence in the record, NAD recommended that the advertiser discontinue all claims at issue, with one exception: CDNC is a new form of chromium compound, a fact that the advertiser is free to promote. However, NAD recommended that the advertiser modify its “next generation” claims to avoid conveying the message that Zychrome is superior to chromium picolinate.
InterHealth Nutraceuticals, in its advertiser’s statement, reported the company “will modify advertising for Zychrome in accordance with the NAD’s recommendations.”
NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.
Reports: Valeant, Actavis deal put on hold
NEW YORK — A proposal by Canadian drug maker Valeant Pharmaceuticals International to purchase generic drug maker Actavis has fallen through, according to published reports.
According to reports, Valeant was planning to pay more than $13 billion in stock to acquire Actavis, but the deal was put on hold because the companies could not agree to terms of the deal. The deal would create a company worth about $35 billion.
Actavis became the world’s third-largest maker of generic drugs last year when U.S.-based Watson Pharmaceuticals acquired Switzerland-based Actavis. The company announced in January that it would change its name to Actavis.
CRN: Consumer Reports corrects article on vitamin D
WASHINGTON — Consumer Reports recently corrected a story to run in its May issue, titled “Vitamin D: How 32 supplements really measure up," that erroneously identified nine vitamin D/calcium supplement products that the publication claimed exceeded the California Proposition 65 Lead Limit for Reproductive Risk.
The story has been corrected online and now states that “All [of the adult calcium plus Vitamin D supplement products tested] met our quality criteria, which includes meeting label claims of calcium and vitamin D, passing USP dissolution test and not exceeding USP limits for heavy metals.”
“We believe this was an honest mistake by the publication, as the settlement agreements with the State of California are not available on either the California Attorney General’s website or the California Office of Environmental Health Hazard Assessment’s website, and we were glad to see the correction," noted Steve Mister, president and CEO for the Council for Responsible Nutrition, in a release last week. “As importantly as the explanation that the companies were not breaking the law is the fact that consumers need to be reassured that the lead levels do not pose a safety risk."
Even before the correction, the article overall provided positive news for vitamin D and calcium supplement users, Mister noted.